Assembly Biosciences, INC Schedule 13G passive stakes

Janus Henderson Group Ltd. has disclosed beneficial ownership of 1,359,514 shares, representing 6.9% of the outstanding common stock of Assembly Biosciences, Inc.

Farallon Capital Management and affiliated entities report beneficial ownership of 1,604,590 shares, representing 8.1% of Assembly Biosciences' common stock.

Paradigm BioCapital entities and Senai Asefaw, M.D. have jointly filed a Schedule 13G, reporting beneficial ownership of 5.4% of Assembly Biosciences, Inc. common stock as of May 4, 2026.

Farallon Capital Management and its affiliates updated their beneficial ownership in Assembly Biosciences, Inc., reporting a collective 7.8% stake and disclosing recent management changes within their own firm.

Janus Henderson Group plc has reported a beneficial ownership of 8.2% in Assembly Biosciences, Inc., holding 1,341,508 common shares.

RA Capital Management and its affiliates have disclosed a 9.5% beneficial ownership stake in Assembly Biosciences, Inc., including common stock and warrants.

Alexander Schornstein's beneficial ownership in Assembly Biosciences, Inc. has decreased to 3.49%, no longer requiring Schedule 13G filings.

Farallon Capital and its affiliated entities have disclosed a beneficial ownership of 7.3% in Assembly Biosciences, Inc., totaling 1,140,510 common shares.

Commodore Capital LP and related entities have reported a 9.9% passive ownership stake in Assembly Biosciences, Inc., totaling 1,615,981 shares.

Alexander Schornstein has reduced his beneficial ownership in Assembly Biosciences, Inc. to 4.68%, no longer holding a 5% or greater stake.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a passive beneficial ownership of 4.99% in Assembly Biosciences, Inc. as of December 31, 2024.